ArticleMedComm2026
Immunotherapy With Anti-PD-1 Versus Anti-PD-L1 in SCLC: A Comprehensive Retrospective Analysis.
Article in MedComm, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Small cell lung cancer (SCLC) is a highly malignant tumor characterized by strong invasiveness and poor prognosis. Immune checkpoint inhibitors have provided new therapeutic options for SCLC, but their comparative clinical benefit remains unclear. This retrospective study enrolled 171 patients with SCLC treated between January 2016 and June 2023, with follow-up through June 30, 2024, to compare survival and safety profiles between anti-programmed death-1 (anti-PD-1) and anti-programmed death-ligand 1 (anti-PD-L1) inhibitors. Among the 119 patients (69.6%) who received immunotherapy plus chemoradiotherapy, the median overall survival (OS) was 48.3 months, compared with 25.2 months in those who did not receive radiotherapy. Multivariable Cox regression confirmed that liver metastasis and radiotherapy status were independently associated with OS and progression-free survival (PFS). Subgroup analyses revealed that patients younger than 65 years who underwent radiotherapy, particularly those without liver metastasis, achieved longer OS with anti-PD-1 agents. In conclusion, both anti-PD-1 and anti-PD-L1 inhibitors improved the prognosis of SCLC. Patients younger than 65 years receiving radiotherapy and those with limited-stage SCLC may represent populations more likely to benefit from anti-PD-1 therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.